The stock of Celgene Corporation (NASDAQ:CELG) is a huge mover today! About 1.05M shares traded hands. Celgene Corporation (NASDAQ:CELG) has risen 0.59% since March 9, 2016 and is uptrending. It has underperformed by 6.82% the S&P500.
The move comes after 6 months positive chart setup for the $76.26B company. It was reported on Oct, 12 by Barchart.com. We have $121.12 PT which if reached, will make NASDAQ:CELG worth $15.25 billion more.
Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on November, 3. They expect $1.31 EPS, up 16.96% or $0.19 from last year’s $1.12 per share. CELG’s profit will be $989.84 million for 19.26 P/E if the $1.31 EPS becomes a reality. After $1.28 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 2.34% EPS growth.
Celgene Corporation (NASDAQ:CELG) Ratings Coverage
Out of 20 analysts covering Celgene Corporation (NASDAQ:CELG), 17 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 85% are positive. Celgene Corporation has been the topic of 36 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Credit Suisse on Wednesday, January 20. As per Friday, July 24, the company rating was maintained by Cantor Fitzgerald. The rating was initiated by Jefferies with “Buy” on Wednesday, September 9. The firm has “Buy” rating by Canaccord Genuity given on Friday, November 6. The firm earned “Buy” rating on Thursday, January 7 by SunTrust. The rating was initiated by Citigroup on Thursday, February 25 with “Buy”. As per Friday, February 5, the company rating was initiated by Leerink Swann. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by UBS on Friday, November 6. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. Wells Fargo maintained the stock with “Outperform” rating in Friday, December 4 report.
According to Zacks Investment Research, “Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.”
Insitutional Activity: The institutional sentiment increased to 0.99 in Q2 2016. Its up 0.06, from 0.93 in 2016Q1. The ratio increased, as 70 funds sold all Celgene Corporation shares owned while 411 reduced positions. 60 funds bought stakes while 418 increased positions. They now own 587.22 million shares or 5.24% less from 619.66 million shares in 2016Q1.
The Oklahoma-based Trust Com Of Oklahoma has invested 0% in Celgene Corporation (NASDAQ:CELG). Halsey Assoc Ct last reported 3.39% of its portfolio in the stock. Altavista Wealth Mgmt last reported 0.25% of its portfolio in the stock. Bollard Limited Liability Corporation last reported 0% of its portfolio in the stock. Atalanta Sosnoff Capital Llc owns 258,969 shares or 0.85% of their US portfolio. Analytic Investors Ltd Liability Corporation has invested 0.09% of its portfolio in Celgene Corporation (NASDAQ:CELG). Sit Investment Associate owns 103,395 shares or 0.27% of their US portfolio. Lombard Odier Asset Management (Europe) Limited holds 10,922 shares or 0.06% of its portfolio. Mizuho Trust Banking has 0.37% invested in the company for 1.22 million shares. Cobiz Inv Limited Liability Corporation accumulated 0.82% or 32,894 shares. Blackrock Group has 0.34% invested in the company for 6.64 million shares. Martin Currie Ltd reported 110,531 shares or 1.05% of all its holdings. Plante Moran Finance Lc accumulated 0.08% or 1,117 shares. Adage Capital Prtn Grp Inc Limited Liability holds 0.3% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 1.11M shares. The Texas-based Sunbelt has invested 0% in Celgene Corporation (NASDAQ:CELG).
Insider Transactions: Since July 28, 2016, the stock had 0 insider purchases, and 7 selling transactions for $29.76 million net activity. LOUGHLIN JAMES J sold $3.14M worth of stock. The insider HUGIN ROBERT J sold 100,000 shares worth $11.00 million. 56,116 shares with value of $5.82 million were sold by Friedman Michael A on Monday, October 3. KAPLAN GILLA sold 9,710 shares worth $1.03M. 15,000 shares were sold by MARIO ERNEST, worth $1.64 million on Friday, September 23. 43,134 Celgene Corporation (NASDAQ:CELG) shares with value of $4.92 million were sold by CASEY MICHAEL D. On Friday, September 23 BARKER RICHARD W sold $2.22 million worth of the stock or 20,000 shares.
More news for Celgene Corporation (NASDAQ:CELG) were recently published by: Businesswire.com, which released: “Celgene Corporation to Announce Third Quarter 2016 Results on October 27, 2016” on January 11, 2016. Profitconfidential.com‘s article titled: “Celgene Corporation: CELG Stock Charts Are a Must-See” and published on September 21, 2016 is yet another important article.
CELG Company Profile
Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.